Novo Nordisk shares shoot up amid promising results for anti-obesity pill
by Julia Kollewe from Science | The Guardian on (#7048S)
Market value of drugmaker climbs by 6.5bn as trial shows significant weight loss' for pill version of Wegovy
The value of the drugmaker Novo Nordisk has shot up by more than 6.5bn after research showed its new anti-obesity pill resulted in almost as much weight loss as its Wegovy jab, as it races against its US rival Eli Lilly to get a tablet treatment to market.
Stock in the Danish company climbed by more than 4.5% on Thursday morning on hopes it could claw back market share lost to Eli Lilly and cheaper generic versions of GLP-1 drugs. The shares have fallen by nearly 60% in the past year as sales slowed.
Continue reading...